Red Light Holland AI Stock Analysis
Want to see TSE:RHEL full AI Analyst Report?
Red Light Holland (RHEL) AI Stock Analysis
Red Light Holland
(CNQX:RHEL)
Score primarily impacted by weak financial performance from ongoing losses and cash burn despite revenue gains and low debt. Technical weakness from price below moving averages and unattractive valuation due to negative P/E further pressure the result.
Red Light Holland (RHEL) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 10.56M
- Dividend Yield
- ―
- Average Volume (3M)
- 223.98K
- Price to Earnings (P/E)
- -2.1
- Beta (1Y)
- 0.31
- Revenue Growth
- -36.49%
- EPS Growth
- -64.44%
- Country
- Canada
- Employees
- 104
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Red Light Holland Business Overview & Revenue Model
Company Description
Based in Toronto, Ontario, Red Light Holland Corp. is primarily involved in the cultivation, production, and retail of recreational magic truffles for the Dutch market. Beyond its own cultivated offerings, the company also engages in the sourcing, di...
Red Light Holland Financial Statement Overview
Summary
Revenue growth from $0.1M to $4-5M is positive, but persistent net losses, negative cash flows, and equity decline from $34M to $12M create ongoing risks despite low debt.
Income Statement
45NeutralBalance Sheet
50NeutralCash Flow
40Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.20M | 4.20M | 4.94M | 4.75M | 2.33M | 110.96K |
| Gross Profit | 1.33M | 1.23M | 1.91M | 2.02M | 617.68K | 19.35K |
| EBITDA | -4.19M | -4.07M | -3.35M | -6.58M | -8.55M | -4.61M |
| Net Income | -6.10M | -6.10M | -4.04M | -7.63M | -14.37M | -1.64M |
Balance Sheet | ||||||
| Total Assets | 14.57M | 14.57M | 21.22M | 24.08M | 32.94M | 36.30M |
| Cash, Cash Equivalents and Short-Term Investments | 9.05M | 9.05M | 12.27M | 14.17M | 26.62M | 32.78M |
| Total Debt | 286.64K | 286.64K | 2.18M | 1.72M | 1.50M | 866.50K |
| Total Liabilities | 3.35M | 3.35M | 3.87M | 3.82M | 3.78M | 2.24M |
| Stockholders Equity | 11.97M | 11.97M | 17.35M | 20.07M | 28.48M | 34.06M |
Cash Flow | ||||||
| Free Cash Flow | -2.56M | -2.56M | -2.01M | -3.92M | -5.28M | -3.63M |
| Operating Cash Flow | -2.42M | -2.42M | -1.48M | -3.23M | -4.88M | -3.36M |
| Investing Cash Flow | -1.23M | -1.23M | -525.40K | -650.43K | -582.74K | -201.55K |
| Financing Cash Flow | -766.03K | -766.03K | 445.17K | -206.95K | 451.76K | 32.78M |
Red Light Holland Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:RHEL, the sentiment is Neutral. The current price of 0.03 is above the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.03, and below the 200-day MA of 0.03, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 57.04 is Neutral, neither overbought nor oversold. The STOCH value of 83.33 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:RHEL.
Red Light Holland Peers Comparison
Overall Rating
TSE:CURA52Neutral
TSE:CWEB42Neutral
TSE:MUSH42Neutral- TSE:RHEL42Neutral
TSE:RVV39Underperform
TSE:PLTH38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TSE:CURA | 52Neutral | CAD 3.14B | -217.45 | -1.47% | ― | 5.01% | 92.12% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TSE:CWEB | 42Neutral | CAD 71.89M | -0.86 | -139.56% | ― | -9.90% | -35.35% |
| TSE:MUSH | 42Neutral | CAD 4.91M | -500.00 | -2.30% | ― | 52.89% | 98.68% |
| TSE:RHEL | 42Neutral | CAD 15.35M | -2.07 | -41.33% | ― | -36.49% | -64.44% |
| TSE:RVV | 39Underperform | CAD 8.89M | -12.50 | 26.78% | ― | ― | 90.84% |
| TSE:PLTH | 38Underperform | CAD 43.59M | -1.11 | -54.58% | ― | -15.64% | 71.65% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:RHEL | Red Light Holland Corp | 0.03 | -0.00 | -16.67% | |
| TSE:MUSH | Good Shroom Co Inc | 0.10 | 0.01 | 7.53% | |
| TSE:RVV | Revive Therapeutics | 0.02 | 0.01 | 100.00% | |
| TSE:CWEB | Charlotte's Web Holdings (OTC) | 0.24 | 0.11 | 81.48% | |
| TSE:CURA | Curaleaf Holdings (Otc) | 11.21 | 2.72 | 32.04% | |
| TSE:PLTH | Planet 13 Holdings, Inc. | 0.13 | -0.09 | -40.91% |
Red Light Holland Corporate Events
Rhelion Subsidiary Ships PEX010 to King’s College London Study
PositiveFilament Health has shipped PEX010 to King’s College London for the SLEEPY feasibility study, which examines administering psilocybin immediately before sleep to help prevent healthy participants from identifying whether they received the drug. The s...
Filament Ships PEX010 to USC for Psychedelic Therapy Trial
PositiveFilament Health shipped its PEX010 botanical psilocybin drug candidate to USC’s Keck School of Medicine for the Mindfulness Assisted Psychedelic Therapy trial. It is the first shipment under a supply and licensing agreement, with USC sponsoring the s...
Rhelion’s Filament Health to Supply Psilocybin Candidate PEX010 for Swedish Social Anxiety Trial
PositiveRhelion Life Sciences, through its subsidiary Filament Health, has signed a supply and licensing agreement with Sweden’s Linköping University to provide its patented botanical psilocybin candidate PEX010 for the PsiloSAD clinical trial in social anxi...
Rhelion’s Filament to Supply Psilocybin for Belgium’s First Compassionate Use Program
PositiveRhelion Life Sciences, through its wholly owned subsidiary Filament Health, operates in the legal psychedelic sector, specializing in naturally derived psilocybin drug candidates. Its lead product, the patented botanical psilocybin drug candidate PEX...
Rhelion Reappoints Psychedelic Research Leader as Advisor and Moves to Restructure Debt
PositiveRhelion Life Sciences has reappointed leading psychedelic researcher Dr. Robin Carhart-Harris as Scientific Advisor, extending a relationship that began in June 2025. He will provide scientific and strategic guidance, regularly interface with managem...
Rhelion Subsidiary Filament to Supply Psilocybin for UCSF Trial on Meth Use Disorder in People With HIV
PositiveRhelion Life Sciences’ subsidiary Filament Health has signed a licence and supply agreement with the University of California, San Francisco to provide its botanical psilocybin candidate PEX010 for a Phase 2 trial. The study will evaluate whether a s...
Rhelion Unit Ships Psilocybin Candidate for PTSD Trial in Calgary
PositiveRhelion Life Sciences, through its subsidiary Filament Health, has shipped its patented botanical psilocybin candidate PEX010 to the University of Calgary for a Phase 2 clinical trial. The study, known as PsiPTSD, will investigate psilocybin-assisted...
Rhelion’s Filament Unit Boosts Psilocybin Supply for Landmark Italian Depression Trial
PositiveRhelion Life Sciences, via its subsidiary Filament Health, has expanded its supply and licence agreement with the University G. d’Annunzio of Chieti-Pescara for its psilocybin drug candidate PEX010 in the TEMPO clinical trial for treatment-resistant...
Rhelion Subsidiary Filament Health Wins New Canadian Patent for Natural Psilocybin
PositiveRhelion Life Sciences, via its wholly owned subsidiary Filament Health, has secured a new Canadian patent covering psychoactive alkaloid extraction and compositions with controlled dephosphorylation for natural psilocybin. The patent strengthens prot...
Rhelion Subsidiary Supplies Psilocybin for Phase 3 Palliative Care Trial
PositiveRhelion Life Sciences’ subsidiary Filament Health has delivered its standardized botanical psilocybin candidate PEX010 to Bruyère Health Research Institute for a Phase 3, multi-site, placebo-controlled clinical trial in palliative care. The study wil...
Rhelion’s Filament Health inks psilocybin supply deal with Dutch research centre
PositiveRhelion Life Sciences, through its wholly owned subsidiary Filament Health, is advancing naturally derived psilocybin-based therapeutics within the legal psychedelic sector. Filament develops and supplies its patented botanical psilocybin drug candid...
Rhelion’s Filament Health to Supply Psilocybin Candidate PEX010 for USC Mindfulness Trial
PositiveRhelion Life Sciences, via its wholly owned subsidiary Filament Health, operates in the legal psychedelic sector with a focus on developing naturally derived psilocybin therapies. The company leverages Filament’s patented PEX010 drug candidate and ex...
Rhelion Unit Filament Ships Psilocybin Drug to Australia for First-of-Its-Kind FND Trial
PositiveRhelion Life Sciences, via its wholly owned subsidiary Filament Health, has shipped its patented botanical psilocybin drug candidate PEX010 from Canada to Australia. The product will be used at Austin Health in Melbourne in PSI-PHY, an investigator-i...
Rhelion Subsidiary Ships Psilocybin Candidate to Australia for Novel Movement Disorder Trial
PositiveRhelion Life Sciences’ subsidiary Filament Health has exported its patented botanical psilocybin candidate PEX010 from Canada to Australia for the PSI-PHY pilot trial, which will test psilocybin-assisted physiotherapy in adults with refractory motor...
Rhelion Expands Role in EU Psilocybin Access With New PEX010 Delivery to Germany
PositiveRhelion Life Sciences, via its subsidiary Filament Health, has completed an additional shipment of its patented, GMP-manufactured botanical psilocybin candidate PEX010 to Germany’s Central Institute of Mental Health. The drug is being used in Germany...
Rhelion Life Sciences Marks Transformational Quarter With Filament Acquisition and Psychedelic Drug Push
PositiveRhelion Life Sciences reported results for the first quarter of fiscal 2027, highlighting a transformational period marked by the closing of its acquisition of Filament Health and the launch of a new life sciences platform. The deal shifts Rhelion’s...
Rhelion’s Filament Unit Wins New U.S. Patent, Expanding Natural Psilocybin IP Estate
PositiveRhelion Life Sciences, through its subsidiary Filament Health, has strengthened its position in the legal psychedelic drug sector by securing a new United States patent for dephosphorylation-controlled extraction of psychoactive alkaloids. This paten...
Rhelion’s Filament Health Supplies Psilocybin PEX010 for University of Washington Cancer Anxiety Trial
PositiveRhelion Life Sciences, through its subsidiary Filament Health, is strengthening its role in the legal psychedelic therapeutics sector by supplying patented botanical psilocybin to research and compassionate use programs worldwide. Its lead drug candi...
Rhelion’s Filament Health to Harness FDA-Authorized AI Imaging in Psilocybin Alzheimer’s Trial Design
PositiveRhelion Life Sciences’ subsidiary Filament Health has signed a non-binding letter of intent with San Francisco-based Darmiyan to explore integrating Darmiyan’s FDA De Novo authorized BrainSee AI imaging platform into the design of future clinical tri...
Rhelion Life Sciences Names New CFO as Psychedelic Drug Platform Expands
PositiveRhelion Life Sciences, an Ontario-based psychedelic life sciences company, has reshaped its business around pharmaceutical drug development and regulated supply of naturally derived psychedelic medicines following the acquisition of Filament Health....
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 03, 2026